MedTrace Logo

Ellacor® Micro-Coring Technology® in Fitzpatrick Skin Types I-VI, Including Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists

NCT07224880 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2025-12-31

No results posted yet for this study

Summary

The main purpose of the study is to collect information about how the device functions in a variety of treatment areas and skin types and to find out what changes, if any, occur in the skin treated with the study device compared to the skin that wasn't treated including patients receiving GLP-1's, a class of medications that mimic a natural hormone to help control blood sugar and support weight loss. The study will also evaluate side effects that occur with this treatment, if any. Standardized 2D Imaging will be used to quantify reduction of wrinkle severity

Conditions

  • glp1 Agonist
  • Gene Expression
  • Skin Laxity

Interventions

DEVICE

ellacor

dermal non-thermal micro-coring device

Sponsors & Collaborators

  • Cytrellis Biosystems, Inc.

    lead INDUSTRY

Eligibility

Min Age
30 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-14
Primary Completion
2026-01-30
Completion
2026-02-28
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07224880 on ClinicalTrials.gov